Linrodostat

Unassigned

New Medicines

Muscle-invasive bladder cancer - neoadjuvant therapy in combination with nivolumab, gemcitabine and cisplatin

Information

New molecular entity
Bristol-Myers Squibb
Bristol-Myers Squibb

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Indoleamine (2,3)-diooxygenase inhibitor (IDOi) - checkpoint protein involved in generating the immunosuppressive tumor micro-environment that supports tumor growth. 100 mg taken orally every day for 1 year [2].
Overall incidence in the UK of bladder cancer is 11.4 per 100,000 population. Around 30% have involvement of the muscle layer. Around 70% have superficial disease, of which 10% is CIS [1].
Muscle-invasive bladder cancer - neoadjuvant therapy in combination with nivolumab, gemcitabine and cisplatin
Oral